Sprint Bioscience enters into collaboration with US Drug Development Company on tumor metabolism program
Sprint Bioscience AB (publ) (Sprint Bioscience) and a US drug development company (Company) have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism. Under the agreement, Sprint Bioscience licenses a PIP4k2a inhibitor program targeting tumor metabolism to the Company. Subsequently, the Company will have full control over further development and worldwide commercialization rights for potential cancer therapeutics and diagnostics. “We are really happy to have closed